Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Sep
22
2021
Elijah E. Cummins Lower Drug Costs Now Act: The Long and Winding Road to Drug Pricing Reform Sheppard, Mullin, Richter & Hampton LLP
Nov
22
2021
FDA Joins Other Regulators in Focus on AI and Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2014
Review – U.S. Patent and Trademark Office Subject Matter Eligibility Guidelines Sheppard, Mullin, Richter & Hampton LLP
Mar
24
2022
HHS OIG Signs Off on Substance Use Recovery Incentive Program Sheppard, Mullin, Richter & Hampton LLP
Dec
5
2014
Now That That’s Settled: The Status of Class Action Settlements in the Seventh Circuit after Pella, Radioshack and NBTY Sheppard, Mullin, Richter & Hampton LLP
Mar
17
2015
California Federal Court Finds that Class Action Plaintiffs’ False Advertising Claims are Stripped Bayer Based on Federal Preemption Sheppard, Mullin, Richter & Hampton LLP
Sep
15
2022
California Expands FEHA to Include Off The Job Cannabis Use Sheppard, Mullin, Richter & Hampton LLP
Oct
31
2022
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements Sheppard, Mullin, Richter & Hampton LLP
Dec
6
2022
Don’t Let Drugs Bring You Down: The Importance of an Effective Drug Diversion Program Sheppard, Mullin, Richter & Hampton LLP
Aug
28
2015
What’s in a Name? That Which We Call a Biological Product… Sheppard, Mullin, Richter & Hampton LLP
Jan
19
2016
Extending Patentable Life of 3D Printers: Lesson From Pharmaceutical Industry Sheppard, Mullin, Richter & Hampton LLP
Jan
22
2020
New Jersey Court Commands Cannabis Reimbursement in Workers’ Compensation Dispute Sheppard, Mullin, Richter & Hampton LLP
Jun
6
2023
FDA Clarifies Approach to Pediatric Drug Development Sheppard, Mullin, Richter & Hampton LLP
Apr
7
2020
Nota Bene Episode 73: “Quarantine and Chill”: Will COVID-19 Impact the Cannabis Industry? with Whitney Hodges Sheppard, Mullin, Richter & Hampton LLP
Jun
18
2020
President Of Medical Technology Company Charged For Promoting Fake COVID-19 Treatment Sheppard, Mullin, Richter & Hampton LLP
Mar
15
2017
Foreign Investment Under Trump Administration Sheppard, Mullin, Richter & Hampton LLP
Dec
4
2020
Cannabis Gets Go-Ahead from House, But Still Faces Hurdles Before Federal Legalization Sheppard, Mullin, Richter & Hampton LLP
Jul
10
2017
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2013
The Food and Drug Administration (FDA) Releases Long-Awaited Final Guidance on Mobile Medical Applications Sheppard, Mullin, Richter & Hampton LLP
Jun
3
2014
Northern District of California Courts Still Searching for Sweet Spot in “Evaporated Cane Juice” Cases: Confusion Over Applicability of Primary Jurisdiction to ECJ Claims Continues Sheppard, Mullin, Richter & Hampton LLP
Apr
17
2019
New York City Council Passes Legislation Banning Marijuana Testing of Job Applicants Sheppard, Mullin, Richter & Hampton LLP
Apr
22
2019
FDA Issues Warning Letter to Lab Marketing Three Laboratory-Developed Tests Sheppard, Mullin, Richter & Hampton LLP
May
11
2022
Warning! FDA Issues Warning Letters for Products Containing Delta-8 THC Sheppard, Mullin, Richter & Hampton LLP
Nov
4
2014
Mobile Health Apps are in a Boom Phase – Why is it so Hard for Pharmaceutical Companies to Find Users? Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
Supreme Court Rules for Physicians in Blow to DOJ Sheppard, Mullin, Richter & Hampton LLP
Jul
21
2022
FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU) Sheppard, Mullin, Richter & Hampton LLP
Jul
29
2019
Delaware Supreme Court Allows Caremark Claim to Proceed Against Directors of Ice Cream Manufacturer Following Listeria Outbreak Sheppard, Mullin, Richter & Hampton LLP
Oct
13
2022
OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies Sheppard, Mullin, Richter & Hampton LLP
Feb
22
2023
CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2023
On the Horizon: Broad Employment Protections for Marijuana Users in the District of Columbia Sheppard, Mullin, Richter & Hampton LLP
Jun
16
2023
FDA Issues First Untitled Letter of the Year to Xeris Pharmaceuticals Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2023
Commercial Cannabis Permit Program and Overlay District Statutorily Exempt Under CEQA Guideline Section 15183 Sheppard, Mullin, Richter & Hampton LLP
Apr
21
2020
Telehealth and Online Prescribing: COVID-19 Triggers Changes to the Prescriber/Patient/Pharmacist Relationship Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2023
Overview of Recent Anti-Corruption Enforcement Actions in the Pharmaceutical Industry in China Sheppard, Mullin, Richter & Hampton LLP
Oct
14
2016
Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins